{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T18:45:29Z","timestamp":1763837129563},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T00:00:00Z","timestamp":1438214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s12032-015-0669-9","type":"journal-article","created":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T04:00:49Z","timestamp":1438142449000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Ibrutinib: from bench side to clinical implications"],"prefix":"10.1007","volume":"32","author":[{"given":"Davide","family":"Grisafi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Maestro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Grumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovica","family":"Piazzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampaolo","family":"Tirone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Tessari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Gianardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milo","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Tasca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,30]]},"reference":[{"issue":"12","key":"669_CR1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nri955","volume":"2","author":"H Niiro","year":"2002","unstructured":"Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol. 2002;2(12):945\u201356. doi: 10.1038\/nri955 .","journal-title":"Nat Rev Immunol"},{"issue":"5573","key":"669_CR2","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1126\/science.1071546","volume":"296","author":"SB Gauld","year":"2002","unstructured":"Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: roles in cell development and disease. Science. 2002;296(5573):1641\u20132. doi: 10.1126\/science.1071546 .","journal-title":"Science"},{"issue":"3","key":"669_CR3","first-page":"515","volume":"1","author":"T Kurosaki","year":"1998","unstructured":"Kurosaki T. Molecular dissection of B cell antigen receptor signaling (review). Int J Mol Med. 1998;1(3):515\u201327.","journal-title":"Int J Mol Med"},{"issue":"11","key":"669_CR4","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.molimm.2010.12.007","volume":"48","author":"T Kurosaki","year":"2011","unstructured":"Kurosaki T. Regulation of BCR signaling. Mol Immunol. 2011;48(11):1287\u201391. doi: 10.1016\/j.molimm.2010.12.007 .","journal-title":"Mol Immunol"},{"issue":"1","key":"669_CR5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1200\/JCO.2012.44.4281","volume":"31","author":"A Wiestner","year":"2013","unstructured":"Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton\u2019s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol. 2013;31(1):128\u201330. doi: 10.1200\/JCO.2012.44.4281 .","journal-title":"J Clin Oncol"},{"key":"669_CR6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev.immunol.021908.132649","volume":"27","author":"ME Conley","year":"2009","unstructured":"Conley ME, Dobbs AK, Farmer DM, Kilic S, Paris K, Grigoriadou S, et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol. 2009;27:199\u2013227. doi: 10.1146\/annurev.immunol.021908.132649 .","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"669_CR7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","volume":"2","author":"Z Pan","year":"2007","unstructured":"Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, et al. Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase. ChemMedChem. 2007;2(1):58\u201361. doi: 10.1002\/cmdc.200600221 .","journal-title":"ChemMedChem"},{"issue":"29","key":"669_CR8","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075\u201380. doi: 10.1073\/pnas.1004594107 .","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"669_CR9","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"SE Herman","year":"2011","unstructured":"Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287\u201396. doi: 10.1182\/blood-2011-01-328484 .","journal-title":"Blood"},{"issue":"5","key":"669_CR10","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","volume":"119","author":"S Ponader","year":"2012","unstructured":"Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182\u20139. doi: 10.1182\/blood-2011-10-386417 .","journal-title":"Blood"},{"issue":"1","key":"669_CR11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.canlet.2012.08.012","volume":"328","author":"V Audrito","year":"2013","unstructured":"Audrito V, Vaisitti T, Serra S, Bologna C, Brusa D, Malavasi F, et al. Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options. Cancer Lett. 2013;328(1):27\u201335. doi: 10.1016\/j.canlet.2012.08.012 .","journal-title":"Cancer Lett"},{"issue":"1","key":"669_CR12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88\u201394. doi: 10.1200\/JCO.2012.42.7906 .","journal-title":"J Clin Oncol"},{"issue":"2","key":"669_CR13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/10428194.2013.803226","volume":"55","author":"JR Brown","year":"2014","unstructured":"Brown JR. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. Leuk Lymphoma. 2014;55(2):263\u20139. doi: 10.3109\/10428194.2013.803226 .","journal-title":"Leuk Lymphoma"},{"key":"669_CR14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-6-36","volume":"6","author":"M Wu","year":"2013","unstructured":"Wu M, Akinleye A, Zhu X. Novel agents for chronic lymphocytic leukemia. J Hematol Oncol. 2013;6:36. doi: 10.1186\/1756-8722-6-36 .","journal-title":"J Hematol Oncol"},{"issue":"9","key":"669_CR15","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.clinthera.2013.08.004","volume":"35","author":"AV Danilov","year":"2013","unstructured":"Danilov AV. Targeted therapy in chronic lymphocytic leukemia: past, present, and future. Clin Ther. 2013;35(9):1258\u201370. doi: 10.1016\/j.clinthera.2013.08.004 .","journal-title":"Clin Ther"},{"issue":"3","key":"669_CR16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1172\/JCI23409","volume":"115","author":"BT Messmer","year":"2005","unstructured":"Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Investig. 2005;115(3):755\u201364. doi: 10.1172\/JCI23409 .","journal-title":"J Clin Investig"},{"issue":"3","key":"669_CR17","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1158\/1078-0432.CCR-13-0226","volume":"20","author":"E Hacken ten","year":"2014","unstructured":"ten Hacken E, Burger JA. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia\u2013focus on the B-cell receptor. Clin Cancer Res. 2014;20(3):548\u201356. doi: 10.1158\/1078-0432.CCR-13-0226 .","journal-title":"Clin Cancer Res"},{"issue":"2","key":"669_CR18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","volume":"117","author":"Y Herishanu","year":"2011","unstructured":"Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563\u201374. doi: 10.1182\/blood-2010-05-284984 .","journal-title":"Blood"},{"issue":"12","key":"669_CR19","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","volume":"34","author":"JA Burger","year":"2013","unstructured":"Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013;34(12):592\u2013601. doi: 10.1016\/j.it.2013.07.002 .","journal-title":"Trends Immunol"},{"issue":"7415","key":"669_CR20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature11309","volume":"489","author":"M Duhren-von Minden","year":"2012","unstructured":"Duhren-von Minden M, Ubelhart R, Schneider D, Wossning T, Bach MP, Buchner M, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012;489(7415):309\u201312. doi: 10.1038\/nature11309 .","journal-title":"Nature"},{"issue":"3","key":"669_CR21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/leu.2013.358","volume":"28","author":"S Cheng","year":"2014","unstructured":"Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014;28(3):649\u201357. doi: 10.1038\/leu.2013.358 .","journal-title":"Leukemia"},{"issue":"1","key":"669_CR22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. New Engl J Med. 2013;369(1):32\u201342. doi: 10.1056\/NEJMoa1215637 .","journal-title":"New Engl J Med"},{"issue":"13","key":"669_CR23","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMc1309710","volume":"369","author":"JE Neffendorf","year":"2013","unstructured":"Neffendorf JE, Gout I, Hildebrand GD. Ibrutinib in relapsed chronic lymphocytic leukemia. New Engl J Med. 2013;369(13):1277. doi: 10.1056\/NEJMc1309710#SA1 .","journal-title":"New Engl J Med"},{"issue":"1","key":"669_CR24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","volume":"15","author":"S O\u2019Brien","year":"2014","unstructured":"O\u2019Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial. Lancet Oncol. 2014;15(1):48\u201358. doi: 10.1016\/S1470-2045(13)70513-8 .","journal-title":"Lancet Oncol"},{"key":"669_CR25","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1182\/blood.V122.21.675.675","volume":"122","author":"J Burger","year":"2013","unstructured":"Burger J, Keating M, Wierda W, Hoellenriegel J, Jeyakumar G, Ferrajoli A, Faderl S, Cardenas-Turanzas M, Lerner S, Zacharian G, Huang X, Kantarjian H, O\u2019Brien S. Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): new, updated results of a phase II trial in 40 patients. Blood. 2013;122:675.","journal-title":"Blood"},{"issue":"1","key":"669_CR26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2217\/fon.14.119","volume":"11","author":"M Hallek","year":"2015","unstructured":"Hallek M, Kay NE, Osterborg A, Chanan-Khan AA, Mahler M, Salman M, et al. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed\/refractory chronic lymphocytic leukemia. Future Oncol. 2015;11(1):51\u20139. doi: 10.2217\/fon.14.119 .","journal-title":"Future Oncol"},{"issue":"4","key":"669_CR27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/2040620714539906","volume":"5","author":"A Aalipour","year":"2014","unstructured":"Aalipour A, Advani RH. Bruton\u2019s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Therap Adv Hematol. 2014;5(4):121\u201333. doi: 10.1177\/2040620714539906 .","journal-title":"Therap Adv Hematol"},{"issue":"7277","key":"669_CR28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88\u201392. doi: 10.1038\/nature08638 .","journal-title":"Nature"},{"issue":"Suppl. 1","key":"669_CR29","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood.V120.21.686.686","volume":"120","author":"W Wilson","year":"2012","unstructured":"Wilson W, Gerecitano J, Goy A, de Vos S, Kenkre V, Barr P, Blum K, Shustov A, Advani R, Lih J, Williams M, Schmitz R, Yang Y, Pittaluga S, Wright G, Kunkel L, McGreivy J, Balasubramanian S, Cheng M, Moussa D, Buggy J, Staudt L. The Bruton\u2019s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed\/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study [abstract 686]. Blood. 2012;120(Suppl. 1):686.","journal-title":"Blood"},{"issue":"9","key":"669_CR30","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood-2006-02-003921","volume":"108","author":"JM Irish","year":"2006","unstructured":"Irish JM, Czerwinski DK, Nolan GP, Levy R. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood. 2006;108(9):3135\u201342. doi: 10.1182\/blood-2006-02-003921 .","journal-title":"Blood"},{"key":"669_CR31","doi-asserted-by":"crossref","unstructured":"Fowler N, Advani R, Sharman J, Smith S, MvGreivy J, Kunkel L, Troung V, Zhou C, Boyd T. The Bruton\u2019s tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma [Abstract 156]. Presented at the 2012 ASH Annual Meeting December 9, 2012. 2012.","DOI":"10.1182\/blood.V120.21.156.156"},{"issue":"10","key":"669_CR32","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","volume":"37","author":"M Cinar","year":"2013","unstructured":"Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res. 2013;37(10):1271\u20137. doi: 10.1016\/j.leukres.2013.07.028 .","journal-title":"Leuk Res"},{"issue":"6","key":"669_CR33","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. New Engl J Med. 2013;369(6):507\u201316. doi: 10.1056\/NEJMoa1306220 .","journal-title":"New Engl J Med"},{"key":"669_CR34","unstructured":"Study of Ibrutinib (a Bruton\u2019s Tyrosine Kinase Inhibitor), versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma who have received at least one prior Therapy. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01646021 [database on the Internet]. Accessed."},{"issue":"5","key":"669_CR35","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1586\/17474086.2014.951323","volume":"7","author":"N Shah","year":"2014","unstructured":"Shah N, Hutchinson C, Rule S. Ibrutinib for the treatment of mantle cell lymphoma. Expert Rev Hematol. 2014;7(5):521\u201331. doi: 10.1586\/17474086.2014.951323 .","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"669_CR36","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","volume":"122","author":"G Yang","year":"2013","unstructured":"Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood. 2013;122(7):1222\u201332. doi: 10.1182\/blood-2012-12-475111 .","journal-title":"Blood"},{"issue":"15","key":"669_CR37","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstrom\u2019s macroglobulinemia. New Engl J Med. 2015;372(15):1430\u201340. doi: 10.1056\/NEJMoa1501548 .","journal-title":"New Engl J Med"},{"issue":"9","key":"669_CR38","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1182\/blood-2011-12-396853","volume":"120","author":"YT Tai","year":"2012","unstructured":"Tai YT, Chang BY, Kong SY, Fulciniti M, Yang G, Calle Y, et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012;120(9):1877\u201387. doi: 10.1182\/blood-2011-12-396853 .","journal-title":"Blood"},{"issue":"9","key":"669_CR39","doi-asserted-by":"crossref","first-page":"913","DOI":"10.18632\/oncotarget.655","volume":"3","author":"YT Tai","year":"2012","unstructured":"Tai YT, Anderson KC. Bruton\u2019s tyrosine kinase: oncotarget in myeloma. Oncotarget. 2012;3(9):913\u20134.","journal-title":"Oncotarget."},{"key":"669_CR40","author":"MY Murray","year":"2015","unstructured":"Murray MY, Zaitseva L, Auger MJ, Craig JI, MacEwan DJ, Rushworth SA, et al. Ibrutinib inhibits BTK-driven NF-kappaB p65 activity to overcome bortezomib-resistance in multiple myeloma. Cell Cycle. 2015;. doi: 10.1080\/15384101.2014.998067 .","journal-title":"Cell Cycle"},{"issue":"1","key":"669_CR41","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cellsig.2012.09.008","volume":"25","author":"SA Rushworth","year":"2013","unstructured":"Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB. Cell Signal. 2013;25(1):106\u201312. doi: 10.1016\/j.cellsig.2012.09.008 .","journal-title":"Cell Signal"},{"key":"669_CR42","author":"SQ Zhang","year":"2015","unstructured":"Zhang SQ, Smith SM, Zhang SY, Lynn Wang Y. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2015;. doi: 10.1111\/bjh.13427 .","journal-title":"Br J Haematol"},{"issue":"24","key":"669_CR43","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Cheng S, Lu P, Setty M, Perez AR, Guo A, et al. Ibrutinib resistance in chronic lymphocytic leukemia. New Engl J Med. 2014;370(24):2352\u20134. doi: 10.1056\/NEJMc1402716 .","journal-title":"New Engl J Med"},{"issue":"24","key":"669_CR44","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib. New Engl J Med. 2014;370(24):2286\u201394. doi: 10.1056\/NEJMoa1400029 .","journal-title":"New Engl J Med"},{"issue":"10","key":"669_CR45","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","volume":"125","author":"M Tsang","year":"2015","unstructured":"Tsang M, Shanafelt TD, Call TG, Ding W, Chanan-Khan A, Leis JF, et al. The efficacy of ibrutinib in the treatment of Richter syndrome. Blood. 2015;125(10):1676\u20138. doi: 10.1182\/blood-2014-12-610782 .","journal-title":"Blood"},{"issue":"16","key":"669_CR46","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","volume":"125","author":"JC Byrd","year":"2015","unstructured":"Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497\u2013506. doi: 10.1182\/blood-2014-10-606038 .","journal-title":"Blood"},{"issue":"1","key":"669_CR47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-015-0157-x","volume":"8","author":"R Maffei","year":"2015","unstructured":"Maffei R, Fiorcari S, Martinelli S, Potenza L, Luppi M, Marasca R. Targeting neoplastic B cells and harnessing microenvironment: the \u201cdouble face\u201d of ibrutinib and idelalisib. J Hematol Oncol. 2015;8(1):60. doi: 10.1186\/s13045-015-0157-x .","journal-title":"J Hematol Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-015-0669-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-015-0669-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-015-0669-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T16:12:35Z","timestamp":1599408755000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-015-0669-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,30]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["669"],"URL":"https:\/\/doi.org\/10.1007\/s12032-015-0669-9","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,30]]},"article-number":"225"}}